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Small molecule inhibitorThe lateral transmembrane protein–protein interaction has been regarded as “undruggable” despite its
importance in many biological processes. The homo-trimerization of transmembrane domain 5 (TMD-5) of
latent membrane protein 1 (LMP-1) is critical for the constitutive oncogenic activation of the Epstein–Barr
virus (EBV). Herein, we report a small molecule agent, NSC 259242 (compound 1), to be a TMD-5 self-
association disruptor. Both the positively charged acetimidamide functional groups and the stilbene back-
bone of compound 1 are essential for its inhibitory activity. Furthermore, cell-based assays revealed
that compound 1 inhibits full-length LMP-1 signaling in EBV infected B cells. These studies demonstrated a
new strategy for identifying small molecule disruptors for investigating transmembrane protein–protein
interactions.
© 2012 Elsevier B.V. All rights reserved.1. Introduction
Major strides have been made in the development of small
molecule inhibitors of protein–protein interactions (PPI) in the last
15 years despite the inherent challenge of targeting their expansive
protein interfaces [1–3]. However, the development of PPI inhibitors
that target transmembrane domains (TMD) of proteins has lagged be-
hind, primarily due to the hurdle of identifying small molecules that
are able to not only insert into phospholipid bilayers but also speciﬁ-
cally recognize these highly hydrophobic TMDs [4–7].
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l rights reserved.for B cell immortalization [8]. The constitutive signaling activities of
LMP-1 depend on its homo-oligomerization [8]. Recently, we identi-
ﬁed that the ﬁfth transmembrane domain (TMD-5) of LMP-1 medi-
ates its oligomerization [9]. A membrane-embedded aspartic acid
residue (Asp 150) in TMD-5 has been shown to facilitate a hydrogen
bonding network, driving LMP-1 homo-trimeric complex formation
(Fig. 1). Such a hydrogen-bonding network is possible because the
carboxylic acid groups of the aspartic acid residues remain protonat-
ed in a phospholipid bilayer, which is consistent with previous re-
ports that the pKa values of membrane-embedded carboxylic acid
are signiﬁcantly elevated [10]. Mutation of the Asp 150 residue to
Ala abolishes the downstream signaling of LMP-1 (e.g. NF-κB),
suggesting a novel strategy to target LMP-1 by disrupting its lateral
TMD interactions. Herein, we report a small molecule inhibitor that
suppresses TMD-5 oligomerization, thereby inhibiting the LMP-1-
mediated oncogenic signaling.
2. Materials and methods
2.1. Cell based screening
ToxR7–TMD-5, ToxR7–TMD of diacylglycerol kinase (DAGK) and
ToxR7–TMD of integrin αIIb plasmids were constructed as described
previously [11–13]. Diversity Set II library (1364 compounds) was
provided by the Developmental Therapeutic Program, NCI/NIH. Cell
Fig. 2. Structure of NSC 259242 (compound 1) and its analogues.
Fig. 1. (a), Energy-optimized atomistic model [9] of homo-trimeric complex of LMP-1 TMD-5 in explicit membrane bilayers. (b), The TMD-5 association is driven by the H-bonds
mediated by Asp 150.
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ToxR7–TMD-5 plasmid (200 ng) was transformed into 200 μL of
FHK12 competent cells (kindly provided by D. Langosch, Technische
Universität München, Germany) with heat shock at 42 °C for 90 s
and incubation on ice for 2 minutes, followed by addition of 800 μL
SOC media and incubation with shaking at 37 °C for 1 h. 5 μL of the
transformation mixture was used to inoculate 100 μL LB+arabinose
(0.0025%) and chloramphenicol (30 μg/mL) and 100 μM compound.
Cultures were incubated with shaking at 37 °C for 20 h and β-
galactosidase activity was measured using a Beckman Coulter DTX
880 plate reader (Beckman, Coulter, Fullerton, CA, USA) as described
previously [11,12]. Brieﬂy, 5 μL of culture was transferred to the wells
of a Costar 3596 polystyrene 96-well plate (Corning, NY, USA) con-
taining 100 μL Z buffer/chloroform (1% β-mercaptoethanol, 10% chlo-
roform, 89% A buffer: 1 M sodium phosphate, 10 mM KCl, 1 mM
MgSO4 and pH 7.0). Cells were lysed by addition of 50 μL Z buffer/ SDS
(1.6% w/v sodium dodecyl sulfate (SDS) in Z buffer) and shaking at
28 °C for 10 min. 50 μL Z buffer/ONPG (0.4% w/v ONPG in Z buffer)
was added and β-galactosidase activity was measured by monitoring
the reaction at 405 nm for a period of 20 min at 28 °C. Miller units were
calculated using the following equation: Miller units=(OD405/min)/
OD600×1000. Compounds that decreased TMD-5 oligomerization by
50% at the concentration of 100 μM were selected as possible hits. After
ﬁrst round of screening, the identiﬁed possible hits were re-tested their
inhibition toward TMD-5 oligomerization. 26 compounds were found as
potential hits after the ﬁrst and second round of screen. Next, toxicity
test (measuring OD 600 nm) was further carried out to eliminate the
false positive hits owing to the growth inhibition effect.
2.2. Western blotting
The samples were ﬁrst separated by 12% sodium dodecyl sulfate
polyacrylamide gel electrophoresis (SDS-PAGE) and then electro-
blotted to PVDF membrane. After blocking with 5% bovine serum al-
bumin (BSA), the membranes were incubated with 0.5 μg/mL of
MBP primary antibody at room temperature for 2 h. The membranes
were washed 5 times in phosphate buffered saline (PBS, 137 mM
NaCl, 2.7 mM KCl, 8 mM Na2HPO4, 1.46 mM KH2PO4, pH 7.4) solution
with 0.05% of detergent Tween 20 (PBST) for 5 min each and then in-
cubated for 1 h at room temperature with secondary antibody-
horseradish peroxidase (HRP) conjugate (50 ng/mL). After extensive
washing in PBST, the protein–antibody complexes were visualized
by exposure to X-ray ﬁlm after reacting with Super-Signal West
Pico Chemiluminescent Substrate (Pierce, Rockford, IL, USA).
2.3. Peptide synthesis and puriﬁcation
Peptides were synthesized on Rink Amide MBHA resin (100–200
mesh) (Calbiochem-Novabiochem, San Diego, CA, USA) with a substi-
tution level of 0.57 mmol/g. Peptides were synthesized using a CEMLiberty automated synthesizer (CEM, Mathews, NC, USA) with Dis-
covery microwave module at 0.1 mmol scale. The GGPG/GPGG se-
quence motif was included at the N-/C-termini of the peptide to
increase solubility. An additional glycine was added to the N-
terminus of each peptide to act as a spacer for the addition of a
ﬂuorophore. Activation of the free amino acids was achieved using
HATU (0.40 M solution in N, N-dimethylformamide). The reaction
solvent was N-methyl-2-pyrrolidone (HPLC grade, Fisher, Pittsburgh,
PA, USA). Side chain deprotection and simultaneous cleavage from
the resin was performed using a mixture of triﬂuoroacetic acid
(TFA)/water/1,2-ethanedithiol/triisopropylsilane (90:2.5:2.5:1,v/v)
or triﬂuoroacetic acid/water/phenol/thioanisole/1,2-ethanedithiol/
triisopropylsilane (81.5:5:5:5:2.5:1) at room temperature for two
hours. The crude peptides were collected by precipitation with
cold (−20 °C) diethyl ether (Sigma-Aldrich, St. Louis, MO, USA). The
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reverse phase HPLC system (Santa Clara, CA, USA) with an Agilent
Zorbax 300 SB-C8 column using a linear gradient of buffer A (10% 2-
propanol, 0.1% triﬂuoroacetic acid in Millipore water) and buffer B
(6:3:1 2-propanol/acetonitrile/water containing 0.1% triﬂuoroacetic
acid). The identities of the puriﬁed peptides were conﬁrmed as themo-
nomeric species byMALDI-TOFmass spectroscopy on a Voyager DE-STR
Biospectrometry Workstation (PerSeptive Biosystems, CA, USA).
Peptides were labeled with coumarin using the following meth-
od: 7-Hydroxycoumarin-3-carboxylic acid (100 mg, 0.485 mmol)
and HBTU (186 mg, 0.490 mmol) were dissolved in 1:9 dimethyl
sulfoxide/N,Ndimethylformamide and added to the resin. N,N′-
Diisopropylethylamine (185 μL, 1.06 mmol) was added and the
reaction was stirred for 2–16 h until the Kaiser test indicated that
the reaction was complete. Cleavage and puriﬁcations were per-
formed as described above.
The concentration of TMD-5 peptide (GGPG-WQLLAFFLAFFL
DLILLIIALYL-GPGG)derived from LMP-1was determined by absorbance
at 280 nm using an extinction coefﬁcient of 6990 M−1 cm−1. The
concentration of coumarin labeled TMD-5 peptide (coumarin
-GGGPG-WQLLAFFLAFFLDLILLIIALYL-GPGG) was determined by absor-
bance at 400 nm using an extinction coefﬁcient of 39300 M−1 cm−1.
2.4. Chemical synthesis
Compound 1 (Fig. 2) was provided by NCI/DTP Open Chemical
Repository (http://dtp.cancer.gov). Compound 6 (Fig. 2) (2,2′-(1,2-
ethenediyldi-4,1-phenylene)bis(4,6-diphenyl-1,3,5-triazine)) was pur-
chased from Chembridge (Cat. No. 5255931, San Diego, CA, USA). The
other compounds (Fig. 2) were synthesized and characterized as shown
in the Supplementary Data.
2.5. Fluorescence dequenching assay
Coumarin labeled TMD-5 peptide was dissolved in triﬂuoroethanol
(TFE) with C14 betaine (3-(N,N-dimethylmyristylammonio)propa-
nesulfonate, Sigma-Aldrich, St. Louis, MO, USA). The organic solvent
was evaporated under a stream of nitrogen to generate a thin ﬁlm of
peptide/detergent mixture, which was then dissolved in 50 mM
HEPES (pH=7.4) buffer. 100 μL of coumarin labeled TMD-5 peptide
(100 nM) solution (50 mM HEPES, 150 μM C14 betaine, pH 7.4) with
the indicated concentration of drug was pipetted into black 96-well
plates in triplicate. Samplesweremixed and allowed to sit at room tem-
perature in the dark overnight to reach equilibrium and then excited at
360 nmand emissionwas read at 430 nmusing a Beckman-Coulter DTX
880 Multimode Detector plate reader. Appropriate drug controls were
subtracted from the observed coumarin ﬂuorescence signal to eliminate
the possible interference from drug ﬂuorescence.
2.6. NMR spectroscopy on TMD-5
2.6.1. Sample preparation
Selectively 15N-Gly, Leu, Ala (15N-GLA) labeled and uniformly 13C,
15N enriched TMD-5 peptides (GGPG-WQLLAFFLAFFLDLILLIIALYL-
GPGG) were synthesized and puriﬁed as described previously.
Isotope labeled amino acids were purchased from Cambridge Isotope
Laboratories (Andover, MA, USA) and Sigma-Aldrich (St. Louis, MO,
USA). The bicelles were prepared by mixing 105 mM 1-palmitoyl-2-
oleoyl-sn-glycero-3-phosphocholine (POPC) and 350 mM dihexanoyl-
phosphadtidylcholine (DHPC) with q=0.3 (AvantiLipids, Alabaster,
AL, USA). The peptide/bicelle mixture was resuspended so that the
ﬁnal concentration was 0.5 mM in 10 mM phosphate buffer at pH 7.0
with 10% (v/v) D2O. For the titration, Compound 1 was added incre-
mentally to the TMD-5 sample to yield the molar ratio 1:0.5, 1:1, 1:2,
and 1:4. The concentration of compound 1 was 100 mM in DMSO, andthe ﬁnal concentration of DMSO in the NMR sample was negligible -
maximum 0.25% (v/v).
2.6.2. NMR spectroscopy
For resonance assignment, 2D 1H, 15N-HSQC, 3D HNCO, HNCA,
HN(CO)CA, and CBCA(CO)NH spectra [14] were collected at 37 °C
on VNMRS 800 MHz spectrometer equipped with HCN z-axis gradient
cold probe. For Compound 1 titrations, the amide proton and nitrogen
resonances were detected using SOFAST HMQC [15] at 37 °C on
Varian INOVA 500 MHz spectrometer equipped with a triple reso-
nance z-axis gradient probe. Spectra were processed with NMRPipe
[16] and analyzed with Sparky (Goddard, T. D. and Kneller, D. G.,
SPARKY 3, UCSF).
2.7. Bis-Tris gel electrophoresis
Electrophoresis was carried out using precast SDS−PAGE gels
according to manufacturer's instructions (12% NuPAGE 10-well Bis-
Tris gels, Invitrogen, Grand Island, NY, USA). Brieﬂy, after NMR titra-
tion experiment (compound 1 to TMD-5 peptide ratio 4:1), sample
was incubated with equal volume of 2× Laemmli sample buffer
(126 mM Tris–HCl, 20% glycerol, 4% SDS, 0.02% bromphenol blue,
pH 6.8) at 90 °C for 7 min. Electrophoresis was carried out at room
temperature with NuPAGE MES SDS running buffer (Invitrogen,
Grand Island, NY, USA) at 125 mV for 55 min. The resulting gel was
stained using SilverXpress® Silver Staining Kit (Invitrogen, Grand
Island, NY, USA).
2.8. NF-κB assay
The human B lymphoblastoid cell line 721 (Epstein–Barr virus
(EBV)-positive) was kindly provided by Dr Jennifer M. Martin
(University of Colorado, Boulder) and cultured in RPMI medium sup-
plemented with 10% fetal bovine serum (FBS), penicillin (50 unit/mL)
and streptomycin (50 μg/mL). NF-κB reporter cells were constructed
by Cignal Lenti NF-κB Reporter kit (SABiosciences, MD, USA) and se-
lected by puromycin treatment according to manufacturer's instruc-
tions. The ﬁreﬂy luciferase gene was placed under the control the
NF-κB transcriptional response element. Brieﬂy 50 μL of B 721 cells
(105 cells/mL) was added to one well of 96-well plate. 50 μL of NF-
κB Reporter letivirus suspension (SABiosciences, MD, USA) was
added. 8 μg/mL of SureENTRY Transduction Reagent (SABiosciences,
MD, USA) was also added to increase the transduction efﬁciency.
After further 48 h incubation, 4 μg/mL puromycin was added to select
transduced cells.
B lymphoblastoid cell line 721 NF-κB reporter cells were seeded at
a density of 1×104 cells/well in 96-well plates (100 μL/each well).
After overnight incubation, different concentrations of compounds
were added to the cells. Following 48 h of treatment, the NF-κB activ-
ity was detected by Steady-Glo Luciferase Assay System (Promega,
Madison, MI, USA) according to manufacturer's instructions. Brieﬂy,
75 μL Steady-Glo Luciferase Assay reagent was added to each well
and incubated at room temperature for 15 min. The luminescence
was measured by Beckman Coulter DTX880 reader (Beckman Coulter,
CA, USA).
2.9. Nitric oxide (NO) assay
Human B lymphoblastoid cell line 721 was seeded at a density of
1×104 cells/well in 96-well plates. After overnight incubation, indi-
cated concentrations of compounds were added. Following an addi-
tional 48 h treatment, 20 μL of media was removed and added to
ﬂat black 96-well microﬂuor plates (Thermo Scientiﬁc, MA, USA).
80 μL of water was added to each well. Subsequently, 10 μL of 2, 3-
diaminonaphthalene (0.05 mg/mL in 0.62 M HCl) was added to each
well and incubated for 15 min. The reaction was quenched by
Fig. 3. (a), Schematic representation of the ToxR assay used for screening LMP-1 TMD-5 disruptors. (b), Coumarin ﬂuorescence dequenching assay. Compounds were added into
100 nM of coumarin-labeled TMD-5 solution (50 mM HEPES, 150 μM C14 betaine, pH=7.4) and equilibrated overnight. Samples were excited at 360 nm and emission was read
at 430 nm using a Beckman-Coulter DTX 880 Multimode Detector plate reader. The background correction and the ﬂuorescence of inhibitors were subtracted from the observed
coumarin ﬂuorescence signal. The ﬂuorescence intensity of control sample (no compound) was set as 1.0. (c), ToxR measurement of the inhibitory effect of compound 1 on the
oligomerization of LMP-1 TMD-5 and TMDs of diacylglycerol kinase (DAGK) and integrin αIIb. TMD oligomerization activity in the absence of compound was normalized as
100%. Western blot showed the chimeric MBP–TMD–ToxR protein expression level and gel loading normalized by OD600 nm of cultures. (d), Fluorescence dequenching assay of com-
pound 1 and its analogues. Experiments were carried out as described in (b). (e), Dose-dependent titration of 1 and 4 on TMD-5 oligomerization using the ToxR assay. (f), ToxR
measurement of oligomerization of TMD-5 in the presence of compound 1 or its analogues. Western blot showed the chimeric MBP–TMD-5–ToxR protein expression level and
gel loading normalized by OD600 nm of cultures. (g), the dose dependent ﬂuorescence enhancement curves of coumarin-labeled TMD-5 induced by compound 4 and compound
5. Experiments were carried out as described in (b).
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Coulter DTX880 reader (Beckman Coulter, CA, USA) with excitation
at 360 nm and emission at 430 nm.
2.10. Cell proliferation assay
Human B lymphoblastoid cell line 721 was seeded at 96 well plate
with a density of 5×104 cells per mL. After overnight incubation, dif-
ferent concentrations of compounds were added. Following 48 h
stimulation, plates were centrifuged and washed by PBS twice.
100 μL of fresh medium was added to each well along with 20 μL of
Cell Proliferation Reagent WST-1 (Roche Diagnostics GmbH,
Mannheim, Germany). After further incubation in a 37 °C chamber
for 1 h, the absorbance at 450 nm was measured on a Beckman-
coulter DTX 880 microplate reader. A wavelength of 620 nmwas cho-
sen as the reference wavelength. The A450 nm–A620 nm for the control
group was set as 100%.
2.11. Kinase proﬁling
The kinase proﬁling was performed by Luceome Biotechnologies,
Tucson, AZ. NSC 259242 was ﬁrst evaluated for false positive against
split luciferase and found it did not inhibit luciferase control. NSC
259242 (50 μM)was then proﬁled in duplicate against the following ki-
nases: AKT1, CAMK1, DDR2, GSK3α, MARK1,MET, PAK1, PDGFRB, PIM1,
PKC-γ, PKL4, and SRC using the protocol described by Ghosh and
co-workers [17]. The percent inhibition and percent activity remaining
was calculated using the following equations: %inhibition=(ALUcontrol
−ALUsample)/ALUcontrol×100 and % activity remaining=100%−% inhi-
bition. Staurosporine (10 μM) was served as the positive control for
kinase inhibitor.
2.12. Statistical analysis
Data are expressed as mean±s.d. and analysis of variance was
carried out using Student's t test with Origin 7.5 (OriginLab Corpora-
tion, Northampton, MA, USA), where pb0.05 was considered
signiﬁcant.
3. Results and discussions
We utilized a previously established ToxR assay as the platform for
screening TMD disruptors in cellular membranes (Fig. 3a) [11–13].
This E. coli-based assay uses a chimeric construct made of the N-
terminal DNA binding domain of ToxR and the monomeric anchor
maltose binding protein (MBP) fused to the LMP-1 TMD-5 cytoplas-
mic and periplasmic termini, respectively. The chimeric plasmid was
then transformed into the FHK12 E. coli competent cells. MBP local-
izes to the periplasm, forcing a parallel orientation of TMD-5 in the
membrane. Oligomerization of TMD-5 brings the fused ToxR in
proximity, promoting binding to the cholera toxin (ctx) promoter
and initiation of lacZ transcription. The lacZ transcription in turn pro-
duces β-galactosidase, which is monitored by the conversion of the
O-nitrophenyl ß-galactoside (ONPG) to O-nitrophyenylate by β-
galactosidase. A small molecule that disrupts the TMD-5 trimerization
will inhibit the LacZ activation, resulting in a decrease of the β-
galactosidase production level.
The NCI Diversity Set II library was screened using our ToxR re-
porter assay. Compounds that decreased TMD-5 oligomerization
greater than 50% at 100 μM were selected as preliminary hits. After
the initial screen, 26 compounds were found as potential oligomeri-
zation inhibitors. Because the stock of these compounds was in
DMSO solution, the effect of DMSO on TMD-5 oligomerization was in-
vestigated. It was found that, at concentrations up to 2%, DMSO
showed negligible effects (Supplementary Figure S1). Toxicity tests
were also carried out to eliminate the false positives due to thecompounds inhibitory effect on E. coli cell growth. Four compounds
were selected after the second round of screen: NSC 259242 (com-
pound 1, Fig. 2), NSC 47147, NSC 636820 and NSC 67436 (Supple-
mentary Figure S2).
Fluorescence dequenching assays (Supplementary Figure S3) were
performed to biophysically test whether TMD-5 is the direct target of
these identiﬁed small molecule inhibitors. Coumarin-labeled TMD-5
peptide (Coum-GGGPG-WQLLAFFLAFFLDLILLIIALYL-GPGG) was syn-
thesized following standard solid phase peptide synthesis (SPPS) proce-
dure for hydrophobic peptides. Two –GGPG- tags were appended onto
either terminus of TMD-5, serving as both a ﬂexible linker to the ﬂuo-
rescence dye as well as a facilitator of membrane insertion [18]. TMD-
5 forms homo-trimer in the presence of 150 μM C14 betaine (critical
micelle concentration=100 μM), resulting in coumarin ﬂuorescence
self-quenching [9]. Disruption of the TMD-5 oligomer dequenches the
coumarin dye, leading to ﬂuorescence enhancement. Among the four
initial hits, only compound 1was found to be able to efﬁciently disrupt
TMD-5 homo-trimeric association, and reverse the coumarin ﬂuores-
cence quenching (Supplementary Figure S4). Also importantly, in the
absence of C14 betaine detergent, 1 failed to cause coumarin labeled
TMD-5 ﬂuorescence increase (Fig. 3b). These results eliminate the pos-
sibility that the ﬂuorescence increase was due to interaction between
the coumarin dye and compound 1.
To demonstrate the speciﬁcity of 1, we tested its inhibitory effect
on the diacylglycerol kinase (DAGK), a well studied 3-pass integral
membrane protein that, like LMP-1, also forms a homo-trimer com-
plex through TMD association [11]. As shown in Fig. 3c, compound
1 did not inhibit DAGK TMD oligomerization, conﬁrming the speciﬁc-
ity of 1 to TMD-5. To further demonstrate the speciﬁcity of 1, we also
tested the effect of 1 on the TMD of integrinαIIb, a single pass integral
membrane protein [13]. No apparent oligomerization inhibition was
observed (Fig. 3c). The effect of compound 1 on MBP–TMD–ToxR
chimeric protein expression was also investigated. Compound 1 did
not affect the TMD chimeric protein expression (Fig. 3c), which elim-
inated the possibility that the observed inhibitory effects of 1 were
due to the reduction of TMD-5 chimeric protein expression.
To further understand the nature of the inhibitory effect of com-
pound 1, we carried out a limited structure-activity relationship
study. Reduction of the oleﬁn backbone of 1 to yield compound 2
resulted in diminished TMD-5 inhibitory activity (Fig. 3d). Compound
3, a fragment of 1, did not inhibit TMD-5 association either (Fig. 3d).
Given the fact that both compounds 2 and 3 containing a hydroxyl
group along with ortho-alkyl substitution are inactive, we concluded
that the meta-hydroxyl benzamidine motif alone is not sufﬁcient to
inhibit TMD-5 trimerization. Removing the hydroxyl group of com-
pound 1 to yield compound 4 resulted in a slight increase of TMD-5
inhibitory activity (Fig. 3e). Dose-dependent titrations of 1 and 4
were performed using ToxR assay. Compound 1 and 4 showed a mod-
erate IC50 of 90.0±10.5 μM and 51.9±39.3 μM, respectively, to dis-
rupt TMD-5 oligomerization in whole cells (Fig. 3e). The results
show the hydroxyl group of compound 1 is not important for its
anti-TMD-5 activity. The cationic acetimidamide groups of 1/4 are
speculated to play a critical role in its membrane insertion and dis-
ruption of the TMD-5 association. Removing the positive charged
acetimidamide groups of 4 to yield compound 5 resulted in loss of
TMD-5 inhibitory activity (Fig. 3f and g). Last, we also tested commer-
cially available compound 6, a stilbene derivative that contains the
same core structure with compound 1 but with the acetimidamide
substituted with 1,3,5-triazine (Fig. 2). As shown in Fig. 3d and f, com-
pound 6 did not inhibit TMD-5 oligomerization. In conclusion, these
ﬁndings imply that the acetimidamide groups and the conjugated pi
system in compound 1 provide complementary electronic and confor-
mational match with TMD-5, conﬁrming that the substituted stilbene
scaffold plays essential roles in compound 1's inhibitory activities.
To further conﬁrm the interaction of compound 1with TMD-5, so-
lution phase nuclear magnetic resonance (NMR) experiments were
14.4
6.0
3.5
kDa
TMD-5 TMD-5+1Marker
Fig. 6. 12% Bis-Tris SDS-PAGE analysis of TMD-5 after NMR titration. The ratio of com-
pound 1 to TMD-5 in TMD-5+1 sample shown here is 4:1. Compound 1 disrupts the
TMD-5 trimer (MW 10.2 kDa) and causes TMD-5 monomer (3.4 kDa) formation. It
should be noted that the loading amount of TMD-5 in lane 2 was greater than that of
lane 3.
Fig. 4. 2D (1H-15N) HSQC spectra (excluding most the Gly region) of the TMD-5 pep-
tides solubilized in bicelles. Red and black contours correspond to the spectrum of uni-
formly 13C, 15N enriched TMD-5 and selectively 15N-GLA labeled TMD-5, respectively.
The spectrum shows nice chemical shift dispersion with well-deﬁned peaks and line
shapes, indicative of a folded, homogenous protein tertiary structure. Residues are
numbered according their position in the native LMP-1 sequence.
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surements were performed at 800 MHz with selectively 15N-Gly, Leu,
Ala (15N-GLA) labeled and with uniformly 13C, 15N-enriched TMD-5
peptides in bicelles composed of 105 mM POPC and 350 mM DHPC
(q=0.3). Backbone resonance assignments (Supplementary Table 1)
were obtained by the analysis of 2D (1H, 15N) heteronuclear singlea
b
Fig. 5. The chemical shift index (CSI) values of (a) Cα and (b) CO of residues in LMP-1 TMD
condition used in the NMR experiments.quantumcoherence (HSQC) and a number of 3D spectra (Supplementa-
ry Figure S5). Furthermore, the selectively 15N-GLA-labeled sample fa-
cilitated the assignments of these residue types (Gly, Leu, Ala). The
(1H-15N) HSQC spectrum of TMD-5 is well-dispersed (Fig. 4), indicative
of a well-deﬁned protein structure in the presence of bicelles. The
chemical shift indices (CSI) [19–21] of individual residues indicated
that the TMD-5 peptide indeed adopts a native α–helical conformation-5 conﬁrmed that the TMD-5 peptide adopts a native α-helical conformation under the
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heteronuclear multiple quantum coherence (HMQC) NMR measure-
ments were performed at 500 MHz. Titration of 1 induced chemical
shift changes at a number of sites including the deeply buried Asp
150. This is consistent with the observation that Asp 150 plays a critical
role in LMP-1 homo-oligomerization [9]. Further, Bis-Tris SDS-PAGE
(SDS-PAGE is widely used as a membrane mimetic gel to study TMD
oligomerization [22]) of the NMR samples before and after the titration
demonstrated that compound 1 indeed disrupts the TMD-5 trimer
(MW. 10.2 kDa), resulting in TMD-5 monomer (3.4 kDa) formation
(Fig. 6). Future NMR experiments at high-ﬁeld (800–900 MHz) will
yield greater spectral resolution and allow site-speciﬁc identiﬁcation
of all residues involved in compound 1 binding.
Lastly, compound 1's ability to block full-length LMP-1 oligomeri-
zation in cells was studied by monitoring the down stream NF-κB sig-
nal transduction. LMP-1 acts as a CD40 mimic, interacts with
intracellular signaling proteins TNF receptor associated factors
(TRAFs) and activates the downstream effector NF-κB pathway to
regulate B cell survival, proliferation, and differentiation [8,9]. The
immortalized EBV positive B 721 cell line was used for investigating
the effect of 1 on LMP-1 signaling. Stable NF-κB reporter cell line
was constructed by transfecting B 721 cells with luciferase NF-κB re-
porter lentivirus and selected by antibiotic puromycin. As shown in
Fig. 7a, treatment of 1/4 abolished NF-κB activation in the EBV
positive B 721 cell, with an IC50 of 29.6±6.6 μM /19.1±1.9 μM, re-
spectively. In contrast, compound 2, 3, 5 and 6 demonstrated signiﬁ-
cantly lower inhibitory activities against NF-κB (2, IC50=107.9±
7.5 μM; 3, IC50>200 μM; 5, IC50>200; 6, IC50=180.4±27.5 μM). It
is interesting to note that 1 demonstrated elevated inhibitory potency
in the EBV positive B 721 cell than in the ToxR assay in bacteria, per-
haps due to a better recognition of the full-length protein in more
native-like mammalian cell membranes.
Nitric oxide (NO), produced by inducible NO synthase (iNOS), is a
downstream signal molecule of NF-κB pathway. To further conﬁrm
the effect of compound 1 on NF-κB signaling, the production of NOwas measured. Compound 1/4 (100 μM) was found to suppress NO
over-production in EBV positive B 721 cells, while 2, 3, 5 and 6
show no signiﬁcant inhibition activity (Fig. 7b). It should be noted
that none of the small molecules tested showed cytotoxicity at
100 μM (Fig. 7c), which eliminated the possibility that the observed
inhibition of NF-κB activity and NO production was due to non-
speciﬁc cell death. Compound 1 was further examined for its
speciﬁcity against TMD-5 by screening 12 representative kinases
(AKT1, CAMK1, DDR2, GSK-3α, MAPK1, MET, PAK1, PDGFRB, PIM1,
PKC-γ, PLK4, and SRC) [17]. Ten out of twelve kinases examined
retained >95% of their activity in the presence of 50 μM compound
1 (Fig. 7d). Two kinases, CAMK1 and PDGFRB, showed approximately
20% inhibition under the same condition. These results suggest that
the active dose of compound 1 required to inhibit LMP-1-induced
NF-κB activation did not substantially perturb the activities of these
essential kinases. Taken together, these data showed that compound
1 speciﬁcally inhibits LMP-1 signaling in the EBV-infected B cells.
4. Conclusions
In summary, we have identiﬁed novel LMP-1 TMD-5 homo-
trimerization disruptors. Compound 1 has been shown to disrupt
the TMD-5 association. Furthermore, compound 1 inhibits LMP-1 sig-
naling in EBV infected B cells. Even though only mild potency (~μM)
was achieved, our studies provided a proof-of-concept that the lateral
TMD interactions could be modulated by small molecule agents.
These results might lead to a generally applicable strategy to identify
PPI inhibitors of multi-pass membrane proteins by screening against
isolated individual TMDs.
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